Table 1 Characteristics of selected systematic reviews and outcomes
From: Avoidable waste of research related to outcome planning and reporting in clinical trials
Review characteristics | n = 290 |
|---|---|
|  | Median (Q1–Q3) |
 No. of trials per review | 11 (5–21) |
 No. of trials in the main comparison | 5 (3–12) |
 No. of comparisons per review | 2 (1–5) |
Cochrane review groups | n = 290 |
| Â | No. (%) |
 Airways | 21 (7) |
 Menstrual disorders and subfertility | 20 (7) |
 Anesthesia | 18 (6) |
 Oral health | 15 (5) |
 Schizophrenia | 15 (5) |
 Hepato-biliary | 12 (4) |
 Neuromuscular disease | 12 (4) |
 Musculoskeletal | 11 (4) |
 Infectious diseases | 10 (3) |
 Other | 156 (54) |
Type of assessed intervention | n = 290 |
| Â | No. (%) |
 Pharmacological | 175 (60) |
 Non-pharmacological | 115 (40) |
Outcomes characteristics | n = 141 |
 No. of outcomes per SoF table, median (Q1–Q3) | 5 (3–7) |
 No. of trials per meta-analysis, median (Q1–Q3) | 3 (2–7) |
Outcome categories | n = 1414 |
| Â | No. (%)* |
 Function | 384 (27) |
 Other clinical events | 198 (14) |
 Adverse events; side effects | 174 (12) |
 Mortality | 138 (10) |
 Quality of life | 98 (7) |
 Biological variables | 89 (6) |
 Process, resource use | 74 (5) |
 Pain | 71 (5) |
 Physiological variables | 56 (4) |
 Compliance | 45 (3) |
 Therapeutic decision | 33 (2) |
 Satisfaction with care | 24 (2) |
 Radiological variables | 23 (2) |
 Cost-effectiveness | 16 (1) |